Haemocomplettan

Haemocomplettan is a human fibrinogen product supplied as an intravenous solution. It contains purified human fibrinogen as the active ingredient and is marketed in the European Union. The preparation is used under prescription to replace deficient fibrinogen in patients with congenital or acquired disorders, supporting normal clot formation. The therapy aims to restore adequate plasma fibrinogen levels, facilitating thrombin‑mediated fibrin generation and hemostasis and may be administered in clinical settings.

Haemocomplettan is indicated for the replacement of fibrinogen in several clinical situations where low fibrinogen contributes to bleeding risk.

- Congenital fibrinogen deficiency such as afibrinogenemia or hypofibrinogenemia. - Acquired fibrinogen deficiency secondary to massive transfusion, liver disease, or disseminated intravascular coagulation. - Bleeding associated with major trauma or surgery when plasma fibrinogen levels are below therapeutic thresholds. - Management of hemorrhage in obstetric complications, such as postpartum hemorrhage, where fibrinogen depletion is documented. - Adjunctive therapy during cardiac surgery or cardiopulmonary bypass to maintain hemostasis.

Adverse reactions reported with Haemocomplettan are generally related to infusion and immunologic responses.

Common: - Mild fever or chills during infusion. - Transient headache. - Nausea or vomiting. - Localized erythema or swelling at the infusion site. - Elevated blood pressure that resolves after completion.

Serious: - Allergic or anaphylactic reactions, including urticaria, bronchospasm, or hypotension. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Hemolysis or renal impairment. - Transmission‑related infections (theoretical risk from plasma‑derived products).

Use of Haemocomplettan requires careful assessment of patient history and monitoring during and after administration.

- Verify fibrinogen level and indication before infusion. - Monitor for signs of hypersensitivity throughout the infusion and for at least 30 minutes after completion. - Assess risk factors for thrombosis, especially in patients with cardiovascular disease or prolonged immobilization. - Use caution in patients with known plasma protein allergies or a history of severe transfusion reactions. - Consider renal and hepatic function, as impairment may affect clearance. - Avoid use in patients with active disseminated intravascular coagulation unless benefits outweigh risks.

Haemocomplettan may interact with other agents that affect coagulation or increase immunologic risk.

Avoid: - Concurrent administration of pro‑coagulant drugs (e.g., activated factor VII) that could potentiate thrombosis. - Other plasma‑derived products without appropriate monitoring of fibrinogen levels.

Use with caution: - Antifibrinolytic agents such as tranexamic acid, which may increase clot stability. - Heparin or low‑molecular‑weight heparin, requiring careful monitoring of coagulation parameters. - Immunosuppressive therapies that could mask allergic reactions. - High‑dose vitamin K antagonists, as rapid fibrinogen replacement may alter INR targets.